Taysha Gene Therapies, an early stage biotech developing AAV-based gene therapies for CNS disorders, announced terms for its IPO on Thursday.
The Dallas, TX-based company plans to raise $125 million by offering 6.6 million shares at a price range of $18 to $20. At the midpoint of the proposed range, Taysha Gene Therapies would command a fully diluted market value of $725 million.
Founded in partnership with The University of Texas Southwestern Medical Center (UT Southwestern), Taysha Gene Therapies is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations. One of its most advanced candidates, TSHA-101, is being developed for the treatment of GM2 gangliosidosis. The company plans to initiate a Phase 1/2 trial for TSHA-101 under a CTA in Canada by the end of 2020. In addition, it plans to submit INDs for four additional programs to the FDA by the end of 2021.
Taysha Gene Therapies was founded in 2019 and plans to list on the Nasdaq under the symbol TSHA. Goldman Sachs, Morgan Stanley and Jefferies are the joint bookrunners on the deal. It is expected to price during the week of September 21, 2020.
